Over the weekend, CombiGene received the news that Spark Therapeutics has terminated the collaboration agreement for the epilepsy project CG01. BioStock reached out to CEO Peter Ekolind for a comment on the unexpected announcement and what prompted the decision.
Read the article here: CombiGene’s CEO on the terminated collaboration with Spark – BioStock